Ince Capital | Activity | F4Ince Capital Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Investment
Portfolio company Earendil Labs announced $787 million in financing to scale AI-driven biologics discovery and development.
Earendil Labs
Portfolio company Bambusa Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference.
Milestone
Multiple INCE Capital portfolio companies showcased their products at CES 2026.
INCE portfolio companies at CES 2026
News
Founding Partner JP Gan ranked among 2025 Forbes China's Top 100 Venture Capitalists.
Forbes China's Top 100 Venture Capitalists 2025
Milestone
Portfolio company WEFLY signed 105 eVTOL purchase agreements with three enterprises.
WEFLY
5 investments· SEP 2025 – NOV 2025Show all
Investment
Portfolio company Bambusa Therapeutics announced completion of Series A-2 financing to accelerate next-generation bispecific programs.
Bambusa Therapeutics
Investment
Portfolio company LiblibAI announced $130 million Series B financing.
LiblibAI
Investment
Portfolio company Avenzo Therapeutics announced $60 million Series B financing.
Avenzo Therapeutics
Investment
Dyna Robotics raised $120 million to advance robotic foundation models on the path to physical artificial general intelligence.
Dyna
Investment
Portfolio company Ronovo Surgical closed a Series D financing.
Ronovo Surgical
Milestone
Portfolio company WEFLY successfully test flew its new eVTOL aircraft.
WEFLY
Investment
Portfolio company LiblibAI closed tens of millions of dollars in new financing.
LiblibAI
Team Change
Hired Jireh Li, a former Source Code Capital partner, to lead global initiatives.
Jireh Li joined as Partner